UK markets closed
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • FTSE 250

    22,775.28
    +283.92 (+1.26%)
     
  • AIM

    1,262.60
    +9.91 (+0.79%)
     
  • GBP/EUR

    1.1495
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • BTC-GBP

    41,213.18
    -559.96 (-1.34%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.23 (+0.66%)
     
  • CRUDE OIL

    64.82
    +0.11 (+0.17%)
     
  • GOLD FUTURES

    1,832.00
    +16.30 (+0.90%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     
  • HANG SENG

    28,610.65
    -26.81 (-0.09%)
     
  • DAX

    15,399.65
    +202.91 (+1.34%)
     
  • CAC 40

    6,385.51
    +28.42 (+0.45%)
     

Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031

ReportLinker
·6-min read

Forecasts by Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes), by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Other Drug Type), by Sales Channel (Hospital Pharmacy, Online Suppliers, Retail Pharmacy, Other Sales Channel) AND Regional and Leading National Market Analysis PLUS Analysis of Leading NAFLD & NASH Companies AND COVID-19 Recovery Scenarios

New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031" - https://www.reportlinker.com/p06061840/?utm_source=GNW

What is holding you back in the Non-alcoholic Fatty Liver Disease & NASH Business?
NASH is presently diagnosed by methods such as blood test, imaging or a liver biopsy. These tests are time consuming and have less certainty as they are generic tests. Imaging techniques like CT, MRI and Ultrasound scans were inaccurate to diagnose NASH. These tests are not just incorrect for NASH diagnosis but also cost a lot. This absence of conclusive diagnostic methods in order to detect NASH, is the major challenge to the NASH market.
Our 330+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing non-alcoholic fatty liver disease & NASH market. Buy our report to see how to exploit these opportunities in the global market.
Forecasts to 2031 and other analyses reveal the commercial prospects
. In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
. You find original analyses, with business outlooks and developments.
. Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
Discover sales predictions for the global non-alcoholic fatty liver disease & NASH market and submarkets
Along with revenue prediction for the overall world market, there are 5 segmentations of the non-alcoholic fatty liver disease & NASH market, with forecasts for 5 Disease Cause, 5 Drug Types, 3 Types, 4 Sales Channel each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.
Leading companies and the potential for market growth
As per the analysis, global non-alcoholic fatty liver disease & NASH market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What all Segments Are Covered in the Report?
Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause (COVID-19 Impact Recovery Analysis Covered)
. Hypertension
. Heart Disease
. High Blood Lipid
. Type 2 Diabetes
. Obesity
. Other Disease Causes
Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type (COVID-19 Impact Recovery Analysis Covered)
. Vitamin E & Pioglitazone
. Ocaliva
. Elafibranor
. Selonsertib
. Cencicriviroc
. Other Drug Type
Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel (COVID-19 Impact Recovery Analysis Covered)
. Hospital Pharmacy
. Online Suppliers
. Retail Pharmacy
. Other Sales Channel
Global Non-alcoholic Fatty Liver Disease & NASH Market by Region (COVID-19 Impact Recovery Analysis Covered)
. North America
. Europe
. Asia-Pacific
. Latin America
. Middle East
. Africa
Need industry data? Please contact us today.
Which Key Players Are Leading the Global Market and how much Share do they Hold?

The global market for non-alcoholic fatty liver disease & NASH is ascending and has made significant gains in NASH treatments. The players in the non-alcoholic fatty liver disease & NASH market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
. Mergers and acquisitions.
. Product launches.
. Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the non-alcoholic fatty liver disease & NASH market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 100 pharma companies involved in different aspects of NASH therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.
How the Non-alcoholic Fatty Liver Disease & NASH Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
. What is the current size of the overall global non-alcoholic fatty liver disease & NASH market? How much will this market be worth from 2021 to 2031?
. How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
. Who are the leading companies and what are their activities, results, developments and prospects?
. What are some of the most prominent human non-alcoholic fatty liver disease & NASH currently in development?
. What are the main trends that will affect the world non-alcoholic fatty liver disease & NASH market between 2021 and 2031?
. What are the main strengths, weaknesses, opportunities and threats for the market?
. What are the social, technological, economic and political influences that will shape that industry over the next ten years?
. How will the global non-alcoholic fatty liver disease & NASH market evolve over the forecasted period, 2021 to 2031?
. Which NASH drugs and therapies can succeed and what revenues could they generate to 2031?
. What will be the main commercial drivers for the NASH market from 2021 to 2031?
. How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
. How will that industry evolve between 2021 and 2031, especially in R&D?
Top 20 Leading Players Profiled in the Report
. Pfizer Inc. (Pfizer)
. Roche Holding AG (Roche)
. Takeda Pharmaceutical Company Limited
. Intercept Pharmaceuticals, Inc.
. AstraZeneca PLC
. Novartis AG
. Merck & Co., Inc.
. AbbVie Inc. (AbbVie)
. Gilead Sciences, Inc.
. Genfit Biotechnology
. Cardax, Inc.
. Daewoong Co Ltd
. Madrigal Pharmaceuticals, Inc.,
. Mirum Pharmaceuticals, Inc.
. GW Pharmaceuticals plc.




Read the full report: https://www.reportlinker.com/p06061840/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001